As an important member of multi-nitrogen heterocyclic compounds, quinoxalines have various biological activities which are widely used in chemistry, biomedicine and chemical industry. In this work, quinoxaline derivative 7-bromo-2-(1-methyl-1H-pyrazol-4-yl)quinoxaline (5), which is an essential intermediate to obtain drug Erdafitinib, has been synthesized in reasonably good yield using 4-bromobenzene-1,2-diamine (4) and 2-bromo-1-(1-methyl-1H-pyrazol-4-yl)ethan-1-one (3) as raw materials, triethylene diamine (DABCO) as catalyst, and tetrahydrofuran as solvent. To the best of our knowledge, this is the first time compound 5 has been acquired by the proposed method.
Similar content being viewed by others
References
D. D. Guerreiro, L. F. D. Lima, N. A. R. D. Sa, et al., Res. Vet. Sci., 128, 261 – 268 (2020).
X. Hu, C. Wan, Z. Gan, et al., J. Pharm. Pharmacol., 71(11), 1684 – 1694 (2019).
K. S. Mani, B. Murugesapandian, W. Kaminsky, et al., Tetrahedron Lett., 59(30), 2921 – 2929 (2018).
J. Lin, P. Wang, Z. Zhang, et al., Synthetic Commun., 50(6), 823 – 830 (2020).
T. Wang, Y. Tang, Y. Yang, et al., Bioorg. Med. Chem. Lett., 28(11), 2084 – 2090 (2018).
Y. A. Ammar, A. A. Farag, A. M. Ali, et al., Bioorg. Chem., 99, 103841 (2020).
J. Chakraborty, A. Kanungo, T. Mahata, et al., Chem. Commun., 55(93), 14027 – 14030 (2019).
S. B. Patel, B. D. Patel, C. Pannecouque, et al., Eur. J. Med. Chem., 117, 230 – 240 (2016).
Y. Shirayama, Y. Fujita, Y. Oda, et al., Behav. Brain Res., 390, 112670 (2020).
S. J. Fudemberg, C. Batiste, L. J. Katz. Expert Opin. Drug Saf., 7(6), 795 – 799 (2008).
H. Cerecetto, E. Dias, R. D. Maio, et al., J. Agric. Food Chem., 48(7), 2995?3002 (2000).
J. Cogo, J. Cantizani, I. Cotillo, et al., Bioorg. Med. Chem., 26(14), 4065 – 4072 (2018).
Z. Feng, Z. Gao, W. Qu, et al., RSC Adv., 9(19), 10789 – 10795 (2019).
H. Jiang, Y. Ren, W. Zhang, et al., Angew. Chem. Int. Ed., 132(24), 9410 – 9415 (2020).
N. I. Dhanjal, P. Kaur, D. Sud, et al., Water Environ. Res., 86(5), 457 – 461 (2014)
Z. B. Doganlar, J. Environ. Sci. Heal., 47(11), 1631 – 1643 (2012)
A. Merou, G. Kaklamanos, and G. Theodoridis, J. Chromatogr. B, 11(7), 90 – 95 (2012).
G. Li, F. Yang, L. He, et al., Res. Vet. Sci., 93(3), 1380 – 1386 (2012).
A. Ihsan, X. Wang, W. Zhang, et al., Food Chem. Toxicol., 59, 207 – 214 (2013).
J. Nauseef, D. M. Villamar, J. Lebenthal, et al., Expert Opin. Pharmacother., 21(8), 863 – 870 (2020).
K. Montazeri and J. Bellmunt, Expert Rev. Clin. Pharmacol., 13(1), 1 – 6 (2020).
G. Saxty, C. W. Murray, V. Berdini, et al., WO 2011 / 135376 Al[P]. 2011-11-03.
A. Chaudhari, D. Dhanak, C. A. Donatelli, et al., WO 2008 / 141065 Al[P]. 2008-11-20.
Acknowledgments
The project was funded by the key laboratory of marine bioactive substances and modern analysis technology, SOA (MBSMAT-2017-06)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sun, X., Feng, L., Sun, C. et al. Synthesis of Quinoxaline Derivatives as Intermediates to Obtain Erdafitinib. Pharm Chem J 55, 951–953 (2021). https://doi.org/10.1007/s11094-021-02521-x
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11094-021-02521-x